REJEUNESSE Premium Dermal Fillers: The Ultimate Guide to UPHEC Technology and Monophasic Hyaluronic Acid Volumization

In the highly competitive market of non-surgical facial rejuvenation, medical practitioners and aesthetic clinics look for dermal fillers that offer an optimal balance between safety, longevity, and ease of injection. Traditional hyaluronic acid fillers often face issues with irregular extrusion forces, which can lead to overcorrection or uneven distribution, or they may contain elevated levels of residual cross-linking agents that trigger post-treatment swelling and localized tissue irritation.

To resolve these technical challenges and deliver a predictable, patient-friendly solution, South Korean biopharmaceutical manufacturer Newmedic Co. engineered REJEUNESSE. Holding prominent international health and safety certifications, Rejeunesse is an elite portfolio of monophasic, cross-linked hyaluronic acid fillers. Utilizing a unique chemical engineering process known as UPHEC Technology, the Rejeunesse product line delivers an ultra-pure, highly cohesive gel with excellent elastic properties (G-Prime), making it a top choice for non-surgical facial contouring and wrinkle correction.

For high-volume medical spas, cosmetic clinics, and international aesthetic distributors focused on maximizing clinical success and practice revenue, Rejeunesse represents a highly reliable core inventory asset. Below, we break down the polymer science behind the UPHEC matrix, analyze the specific target indications for each product variant, contrast its rheological behavior with other global brands, and discuss the commercial benefits of volume wholesale sourcing.

The Science of REVOLAX: Patented UPHEC Manufacturing Technology

The exceptional purity, smooth handling, and stability of Rejeunesse are a direct result of its specialized manufacturing protocol, which optimizes the polymer architecture of hyaluronic acid:

• UPHEC Technology (Ultra Pure High Purification Efficient Cross-linking): This unique manufacturing process focuses on maximizing cross-linking efficiency while minimizing the presence of chemical residues. By creating a highly dense, uniform cross-linked network with BDDE, the process yields a stable monophasic gel that is highly resistant to natural enzymatic degradation (hyaluronidase), providing long-lasting aesthetic correction.

• Complete Absence of Free Hyaluronic Acid: The UPHEC process ensures that the final gel matrix is completely cross-linked. The absence of unlinked or free-floating hyaluronic acid molecules means the product does not cause rapid, unpredictable fluid absorption immediately after injection, giving the practitioner absolute control over the final volume.

• Zero Residual BDDE and Low Endotoxins: Following cross-linking, the gel undergoes a multi-stage purification and washing phase. This process extracts virtually all unreacted BDDE cross-linkers and limits trace endotoxins to absolute minimal levels. This ultra-low impurity profile significantly reduces the risk of post-injection swelling, redness, delayed-onset inflammatory nodules, or hypersensitivity reactions.

• Monophasic Cohesive Flow: Rejeunesse is a completely monophasic gel, ensuring a uniform distribution of particle sizes. For the injector, this translates into a smooth, constant, and low extrusion force during administration, allowing for precise control and clean, natural tissue integration.

The Rejeunesse Product Portfolio: Target Calibration

The Rejeunesse family is divided into four distinct formulations, each designed with a unique gel density, viscosity, and injection depth to target specific anatomical zones.

1. Rejeunesse Spark / Rejeunesse Spark Lidocaine

• Rheological Profile: The most fluid, lightweight gel within the portfolio, designed with low injection resistance. It is infused with 0.3 percent lidocaine to maximize patient comfort and is delivered in a 1.1 mL syringe.

• Target Placement Depth: Superficial to mid-dermis layers.

• Clinical Indications: Engineered to smooth out fine, superficial surface lines, treat delicate perioral wrinkles (smoker lines), correct early crow feet around the eyes, and perform subtle skin hydration work.

2. Rejeunesse Fine / Rejeunesse Fine Lidocaine

• Rheological Profile: A soft, uniform monophasic gel combining high fluidity with light structural support. Contains 0.3 percent lidocaine and is delivered in a 1.1 mL syringe.

• Target Placement Depth: Mid-dermis layer.

• Clinical Indications: The gold standard within the line for smoothing early expression lines, managing shallow forehead creases, correcting periorbital imperfections, and executing natural lip augmentations focused on soft hydration and subtle edge definition.

3. Rejeunesse Deep / Rejeunesse Deep Lidocaine

• Rheological Profile: A highly versatile, medium-density monophasic gel that perfectly balances strong lifting capacity with smooth tissue dispersion. Infused with 0.3 percent lidocaine and delivered in a 1.1 mL syringe.

• Target Placement Depth: Mid-to-deep dermis or upper subcutaneous layer.

• Clinical Indications: Optimized for the correction of moderate-to-severe facial folds. It is highly effective for smoothing deep nasolabial folds, lifting distinct marionette lines, adding structural volume to flat lips, and filling shallow temple depressions.

4. Rejeunesse Shape / Rejeunesse Shape Lidocaine

• Rheological Profile: The densest, heaviest formulation within the portfolio, possessing the highest G-Prime and structural projection capability. Contains 0.3 percent lidocaine and is delivered in a 1.1 mL syringe.

• Target Placement Depth: Deep subcutaneous tissue or pre-periosteal (supra-periosteal) placement directly on the bone.

• Clinical Indications: Advanced non-surgical facial sculpting and structural volume restoration. Highly indicated for chin projection, sharp jawline contouring, malar cheek volume replenishment, and non-surgical rhinoplasty adjustments.

Technical Comparison: Rejeunesse vs. Global Competitors

To assist procurement managers, clinic owners, and medical buyers in organizing a balanced clinical menu, it is useful to evaluate how Rejeunesse compares with other leading monophasic and value-driven filler brands like Revolax, Neuramis, and Juvederm.

Characteristic	REJEUNESSE (Newmedic)	REVOLAX (Across)	NEURAMIS (Medytox)	Juvederm (Vycross)
Gel Architecture	Monophasic (Highly cohesive)	Monophasic (Cohesive matrix)	Monophasic (Uniform gel)	Monophasic (Smooth matrix)
Purification Method	UPHEC Technology	High Dialysis Filtration	SHAPE Process	Advanced Dialysis
Lifting Power	High (Excellent shape hold)	High (Strong G-Prime retention)	Intermediate to High	Intermediate to High
Extrusion Force	Extremely low and constant	Low and Constant	Smooth and Fluid	Very smooth, low resistance
Swelling Risk	Extremely Low	Low (Minimal BDDE trace)	Very Low	Low to Moderate
Commercial Value	Exceptional Practice ROI	Strong Balanced Value	Strong Balanced Value	High Corporate Overhead

Key Takeaways for Clinical Positioning:

• Rejeunesse vs. Revolax: Both brands are highly respected South Korean monophasic fillers that offer superb lifting capacity and structural stability. While Revolax is widely known for its high G-Prime density, which is excellent for firm bone contouring, Rejeunesse focuses heavily on minimizing post-injection fluid absorption through its UPHEC cross-linking method. This makes Rejeunesse highly forgiving and predictable, resulting in exceptionally low swelling immediately after treatment.

• Rejeunesse vs. Juvederm: Juvederm is globally recognized for its premium Vycross line, but its high premium brand acquisition costs can significantly reduce a clinic financial margins. Rejeunesse matches the clinical longevity, ease of extrusion, and safety profiles of premium competitors while lowering the unit cost per syringe. This allows practices to design highly attractive, profitable package treatments for their clients without compromising on results.

Wholesale Sourcing and Inventory Management for Clinic Profitability

Because achieving global facial harmony often requires combining treatments across multiple zones during a single patient session (such as combining mid-face cheek lifting with deep nasolabial filling), busy cosmetic centers experience rapid inventory turnover of filler stock.

Sourcing the Rejeunesse portfolio in volume through verified B2B e-commerce channels provides clinics with substantial tier pricing discounts. Minimizing your initial acquisition cost-per-syringe gives your practice the financial agility to handle flexible promotional offers, design seasonal packages, and protect your practice baseline profit margins.

When ordering professional medical devices online, strict logistics and storage parameters must be enforced. True Rejeunesse contains cross-linked polymer chains that are sensitive to extreme temperature shifts. To preserve the structure of the monophasic gel and ensure a smooth, uniform extrusion force during injection, inventory must be stored at room temperature, ideally between 2 degrees and 25 degrees Celsius, away from direct sunlight, moisture, or freezing conditions. Sourcing managers should purchase exclusively from verified wholesale distributors who guarantee authentic original manufacturing from Newmedic Co., unadulterated batch tracking numbers, intact sterile factory seals, and reliable shipping logistics.

Frequently Asked Questions (FAQs)

1. Is Rejeunesse a permanent or temporary filler?

Rejeunesse is a temporary, biodegradable dermal filler. It is made from high-purity, non-animal-based hyaluronic acid. Over time, the body naturally and safely metabolizes the cross-linked gel matrix via normal enzymatic pathways, breaking it down gradually into water and carbon dioxide without leaving any permanent synthetic residues behind.

2. How long do the visible results of a Rejeunesse treatment last?

The durability depends on the specific variant used and the individual metabolic rate of the patient. On average, Rejeunesse Fine lasts between 8 and 12 months, Rejeunesse Deep maintains its volume for 12 to 14 months, and the dense Rejeunesse Shape can hold its structural projection for up to 12 to 18 months. Highly active facial zones like the lips tend to process the gel faster than static areas like the chin.

3. Can Rejeunesse be dissolved if a patient requires correction?

Yes, absolutely. Because Rejeunesse is composed entirely of pure hyaluronic acid without any permanent synthetic additives, it is completely reversible. If a patient experiences asymmetry, overcorrection, or an accidental vascular complication, the gel can be dissolved quickly and completely by injecting a professional hyaluronidase enzyme directly into the treated pocket.

4. Why does Rejeunesse cause less swelling compared to alternative brands?

Post-injection swelling is frequently triggered by residual unreacted cross-linking agents (BDDE) or chemical endotoxins left behind during manufacturing. Rejeunesse utilizes its rigorous UPHEC purification process, which washes the cross-linked gel repeatedly to remove these impurities. Furthermore, because it contains no free, unlinked hyaluronic acid, it does not draw excess water into the tissue right after placement, keeping swelling to an absolute minimum.

5. What is the typical patient recovery profile after a treatment session?

Downtime is minimal, allowing most patients to return to work and light daily activities immediately following their appointment. Normal, temporary inflammatory side effects—such as localized swelling, mild redness, a firm sensation around the injection sites, and light pinpoint bruising—are expected reactions that typically clear completely within 2 to 7 days post-procedure.

6. What are the absolute clinical contraindications for a Rejeunesse treatment?

Rejeunesse must never be administered to pregnant or breastfeeding women, individuals with a known hypersensitivity or systemic allergy to hyaluronic acid or lidocaine, or patients presenting with active skin infections, herpes simplex outbreaks, or open wounds in the target treatment area. It is also completely contraindicated for individuals managing active systemic autoimmune disorders, bleeding conditions, or those taking heavy immunosuppressive medications.